GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures

GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures

Abstract Background Atogepant, the first oral CGRP receptor antagonist approved for migraine prevention, has demonstrated efficacy and safety in randomized clinical trials (RCT). However, prospective real-world data are lacking. Objective To explore the effectiveness, safety, and tolerability of ato...

Full description

Saved in:
Bibliographic Details
Main Authors: Piero Barbanti, Gabriella Egeo, Francesca Pistoia, Cinzia Aurilia, Paola Scatena, Steno Rinalduzzi, Silvia Strumia, Antonio Salerno, Fabio Frediani, Andrea Galli, Massimo Autunno, Laura Di Clemente, Maurizio Zucco, Maria Albanese, Francesco Bono, Pietrantonio Bruno, Laura Borrello, Stefano Messina, Alberto Doretti, Angelo Ranieri, Cecilia Camarda, Rosario Vecchio, Valeria Drago, Giulia Fiorentini, Carlo Tomino, Stefano Bonassi, Paola Torelli, Alice Mannocci, for the Italian Migraine Registry (I-GRAINE) study group
Format: Article
Language:English
Published: BMC 2025-05-01
Series:The Journal of Headache and Pain
Subjects:
Atogepant
Migraine
CGRP
Treatment
Real-world
Disability
Online Access:https://doi.org/10.1186/s10194-025-02068-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s10194-025-02068-2

Similar Items